Meet ApplyKite Twin, the application assistant that learns with you

Meet your Twin, it learns with you

Your Twin learns with you

Launch week codes:30% off annual Pro20% off monthly Pro

Ends in00h00m00s

Mathias Jachs

Medical University of Vienna

Austria

Research Interests

Explore related searches

Professors in Austria

Articles (20)

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Collaborators (9)

Barbara Testoni

Team Leader

FRANCE

View details

Dario Saltini

University of Modena and Reggio Emilia

ITALY

View details

Georg Semmler

Medical University of Vienna

AUSTRIA

View details

Lukas Hartl

Medical University of Vienna

AUSTRIA

View details

Wim Laleman

MD PhD

BELGIUM

View details

Nikolaj Christian Torp

University of Southern Denmark

DENMARK

View details

Thomas Vanwolleghem

Deputy Head

Antwerp University Hospital

BELGIUM

View details

Giovanni B Gaeta

Professor

Università degli Studi della Campania Luigi Vanvitelli

ITALY

View details

Michael Trauner

Professor of Medicine and Chair of Gastroenterology and Hepatology

Medical University of Vienna

AUSTRIA

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Mathias Jachs

Research Interests

Explore related searches

Articles (20)

Predicting hepatic decompensation using non-invasive tests in a contemporary multicentre cohort of patients with cACLD

Correlation of Bile Acid Dynamics to Bulevirtide Response and Disease Severity in Patients With Hepatitis D

Response-guided bulevirtide ± pegylated interferon alfa-2a: Long-term outcomes observed in the nationwide Austrian hepatitis D cohort study

Prognostication of Liver Disease Patients via the WFUMB ‘Rule‐of‐4’ Algorithm Using SSI‐2D‐SWE‐Based Liver Stiffness Measurement

The Alpha‐1 Pi*MZ Genotype Is an Independent Risk Factor for Hepatocellular Carcinoma Development in Patients With ACLD

Biomarkers of Extracellular Matrix Remodelling Are Linked to Severity and Outcome of Advanced Chronic Liver Disease

Indocyanine Green Clearance Correlates With Biomarkers Reflecting Key Disease‐Driving Mechanisms in Advanced Chronic Liver Disease and Predicts Acute‐on‐Chronic Liver Failure and Death

Safety and efficacy of REP 2139-Mg in patients with HDV-related advanced liver disease in an international compassionate access program

Noninvasive test patterns across vascular and parenchymal liver diseases

Changes in SSM Assessed via 100 Hz-VCTE Are Associated With Acute HVPG-Response to i.v. Propranolol: A European Multicentre Study.

Post-TIPS Dynamics of von Willebrand Factor for Risk Stratification After TIPS Placement.

Stage-specific drivers of clinical progression in advanced chronic liver disease.

Role of spot urine analyses in patients with cirrhosis and ascites as the single first decompensation event.

Chronic hepatitis D in Austria

Editorial: Bile Acids Under Bulevirtide—A Pharmacodynamic Signature, Not a Prognostic Biomarker. Authors' Reply

Evolution of liver disease severity and portal hypertension during REP 2139-Mg treatment in 3 patients with chronic hepatitis D

Non-invasive tests to guide hepatocellular carcinoma surveillance

Editorial: ICG‐R15 by PDD—A Simple Dynamic Tool for Refining Risk Stratification in Compensated Advanced Chronic Liver Disease. Authors' Reply

Refining the Baveno VII criteria for clinically significant portal hypertension: An individual patient data meta-analysis

Roadmap for a generally accepted model to predict first hepatic decompensation in compensated advanced chronic liver disease

Collaborators (9)

Barbara Testoni

Dario Saltini

Georg Semmler

Lukas Hartl

Wim Laleman

Nikolaj Christian Torp

Thomas Vanwolleghem

Giovanni B Gaeta

Michael Trauner

Make your next move.